Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who fully understand what the study involves and have signed the consent form voluntarily.
• People who are at least 18 years old at the time of signing the consent form (and no older than 75 for certain groups in this trial).
• People who have a life expectancy of at least 3 months.
• People whose general health and ability to carry out daily activities meets a specific standard (known as ECOG performance status 0 or 1 — confirm with trial site).
• For the early phase of the trial: people whose cancer (any solid tumour that has spread or cannot be surgically removed) has been confirmed by lab testing to carry a specific genetic change called KRAS G12D, and where standard treatments have stopped working, are not tolerated, are not available, or the person is not suitable for or has chosen not to pursue standard treatment.
• For the later phase of the trial: people with confirmed advanced or metastatic pancreatic cancer, bowel cancer, or non-small cell lung cancer that carries the KRAS G12D genetic change, with eligibility also depending on how many prior treatments have been received (confirm with trial site).
• People whose heart, liver, and kidney function meet the required levels.

Who may not be able to join:

• People who have cancer that has spread to the membranes surrounding the brain or spinal cord, or who have active cancer spread in the brain or central nervous system.
• People who have received systemic cancer treatment within 21 days (or within 5 half-lives of the drug, whichever is shorter) before the first dose of the study drug.
• People who have had intensive radiation therapy within 4 weeks, or lower-dose palliative radiation within 1 week, before the first dose of the study drug.
• People who still have unresolved moderate or severe side effects (Grade 2 or higher) from previous cancer treatments, except for hair loss.
• People who have taken part in another clinical trial and received an investigational drug within 21 days or 5 half-lives (whichever is shorter) before the first dose of the study drug.
• People with a history of certain lung conditions, including interstitial lung disease, drug-related lung damage, active lung inflammation, radiation-related lung inflammation needing treatment, or other uncontrolled lung disease.
• People who have experienced a heart attack, unstable chest pain, serious heart failure, stroke, mini-stroke, or a blood clot in the lungs within the past 6 months.
• People who have previously received a treatment specifically targeting the KRAS G12D mutation.
• People who have any serious medical condition, ongoing treatment, or abnormal test results that the doctor running the trial believes could affect the study results or make participation unsafe.

Important: Always verify eligibility with the trial site directly before applying.